Key result
Metabolic dysfunction-associated fatty liver disease was present in 48.9% of ACS patients and independently associated with lower leg strength (p=0.020), gait speed (p=0.003), and 6 MWD (p=0.011).
Why the study?
The relationship between metabolic dysfunction-associated fatty liver disease (MAFLD), physical dysfunction, and prognosis in patients with acute coronary syndrome remains unclear.
Is metabolic dysfunction-associated fatty liver disease associated with impaired physical function and worse prognosis in patients with acute coronary syndrome?
Observational (n=479)
Is metabolic dysfunction-associated fatty liver disease associated with impaired physical function and worse prognosis in patients with acute coronary syndrome?
In patients with acute coronary syndrome, MAFLD is highly prevalent and its coexistence with reduced physical function predicts a higher incidence of adverse clinical events.
MAFLD may identify ACS patients with impaired physical function for targeted rehab; leaves open prognostic impact and need for prospective trials.
It is believed that patients with acute coronary syndrome (ACS) are at an increased risk of nonalcoholic fatty liver disease (NAFLD), which can lead to sarcopenia and physical dysfunction. However, the relationship between metabolic dysfunction-associated fatty liver disease (MAFLD) and physical dysfunction and prognosis remains unclear. We investigated the prevalence of MAFLD in patients with ACS to assess the relationship between MAFLD and muscle strength, walking speed, and 6-min walking distance (6 MWD). We reviewed patients with ACS who were assessed for hepatic steatosis using the fatty liver index, and the results were further assessed to determine the presence of MAFLD. Among 479 enrolled hospitalized patients, MAFLD was identified in 234 (48.9%) patients. Multiple regression analysis revealed that MAFLD was independently associated with lower leg strength, gait speed, and 6 MWD (leg strength, p = 0.020; gait speed, p = 0.003 and 6 MWD, p = 0.011). Furthermore, in multivariate Poisson regression models after adjustment for clinical confounding factors, combined MAFLD and reduced physical functions were significantly associated with a higher incidence of clinical events. MAFLD is common in hospitalized patients with ACS and is associated with impaired physical function. Also, the coexistence of MAFLD and lower physical function predict the incidence of clinical events in patients with ACS.
No takes yet. Share an insight, caveat, or question.
Noda et al. (2022) conducted an observational in Acute coronary syndrome (n=479). Metabolic dysfunction-associated fatty liver disease (MAFLD) vs. No MAFLD was evaluated on Prevalence of MAFLD and its association with physical function (leg strength, gait speed, 6 MWD). Metabolic dysfunction-associated fatty liver disease was present in 48.9% of ACS patients and independently associated with lower leg strength (p=0.020), gait speed (p=0.003), and 6 MWD (p=0.011).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: